Add to Calendar 9/9/2019 10:00:00 AM 9/9/2019 5:00:00 PM Digital Health Impact 2019

Online registration is now closed, there will be a limited number of onsite registrations on Monday

The convergence between digital health and the life sciences is creating new opportunities to transform patient care as well as drug discovery and development. From wearables to machine learning, digital technologies are easing data collection from patients, increasing medical adherence, reshaping clinical trials, and offering new insights into real-world applications of therapies. Embedding digital health tools into the life sciences will also allow new therapies to better work within the growing value-based healthcare system that relies on data and measurable outcomes.

Join MassBio for our inaugural Digital Health Impact 2019 event at the InterContinental Boston at 510 Atlantic Ave, Boston, MA 02210, part of Biotech Week Boston, as we examine the current state of digital health as it relates to the life sciences, the challenges facing its growth, and opportunities for collaboration. Through keynotes, panel discussions, and case studies, we’ll explore new strategies for life sciences and digital health innovators to converge and ultimately deliver better outcomes for patients. Contact Laura Rudberg for sponsorship opportunities. View our sponsorship prospectus here. 

 Intercontinental Boston, 510 Atlantic Avenue, Boston MA, 02210
CEO | Gallop Oncology and EIR at PureTech
Luba Greenwood is a distinguished executive, investor, and company builder with over 20 years of leadership in healthcare and technology, and extensive global board experience. She is the CEO of Gallop Oncology, a clinical stage biotech. She has founded and served as Managing Partner of Dana Farber Cancer Institute venture fund, and CEO and board chair of multiple life sciences companies including Kojin Tx. She is an Entrepreneur-in-Residence at PureTech, where she plays a key role in advancing oncology programs. Luba has a proven track record of building world-class teams and companies, leading over $15B in deals and investments across therapeutics, diagnostics, and life sciences globally. She has held leadership roles at Google (Verily) and Roche, where as VP of Global Business Development & M&A, she spearheaded diagnostics BD and established the East Coast Innovation Hub. Recognized as an industry thought leader, she advises CEOs of top academic institutions, including Dana-Farber Cancer Institute and Wyss Center. She serves on the Investor Committee for National Cancer Institute and contributes to NEJM Catalyst. Luba is a strategic leader in digital transformation, AI, M&A, financing, and governance, with expertise in scaling companies, guiding high-impact transactions, and driving innovation at the intersection of biotech and technology. A former lawyer at WilmerHale, Luba is an expert in regulatory, IP, and corporate law. She has served as a Harvard University lecturer and sits on multiple public and private boards, including In8Bio, BenchSci, Stalicla, Abcam (where she led its sale to Danaher), Closed Loop Medicine, and MassBio.

Brought to you by